Shanghai, PR China – July 2nd, 2013 During the recent ChinaBio® Partnering Forum 2013 event held in Beijing, Luqa’s CEO Robert Braithwaite was interviewed along with RuiYi´s CeO Paul Grayson by Debra Yu of Labrador Advisors.
The interview explored the story of these two China startups with several similarities and some distinct differences. Both focus on drug development in China. Both were founded by Westerners and initially funded by Western investors. Both started in 2010 and are based in Shanghai. However, Luqa being a specialty pharma focuses on rapid commercialization of products for the China market, while RuiYi is focused on the discovery and development of novel biologics for the global market.
During this interview Robert explained the opportunities that Luqa sees in the rapidly evolving China landscape and tried to demystify the China challenge. Key takeaways were the belief that an on-the-ground presence and market understanding makes one realise that “China is NOT different” and how partners can work together to build sustainable brand value in this exciting phase of China´s healthcare industry.
Interviewer: Debra Yu – Labrador Advisors
Robert Braithwaite – Luqa Pharmaceuticals
Paul Grayson – RuiYi, Inc.
Luqa Pharmaceuticals is a China-based, product focused company that acquires, develops and commercializes innovative healthcare products suited to the needs of China. Luqa’s innovative product portfolio is designed to meet the needs of patients, healthcare institutions and physicians in the rapidly changing healthcare market of China. Luqa’s focus is on its products, identifying and investing in assets that will become leading and recognized brands in the therapeutic and channel niches they operate. Please visit us at www.luqapharma.com.